Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Eli Lil­ly has tapped an­oth­er gene edit­ing part­ner, this time look­ing to go af­ter a large pa­tient pop­u­la­tion in the car­dio­vas­cu­lar space with the help of Verve Ther­a­peu­tics.

As part of an in vi­vo gene edit­ing deal, the In­di­anapo­lis Big Phar­ma will pay the Boston biotech $30 mil­lion in cash, in­vest $30 mil­lion via eq­ui­ty at a 15% pre­mi­um to the 30-day vol­ume-weight­ed av­er­age price, and con­tribute up to an­oth­er $465 mil­lion in R&D and com­mer­cial mile­stones, Verve CEO and co-founder Sekar Kathire­san told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER